Investing.com -- Copenhagen-listed shares in Novo Nordisk (CSE:NOVOb) edged up by 3.8% on Thursday, touching a fresh record high. The Danish pharmaceutical giant has seen its share price surge by ...

Sanders opened the hearing by displaying charts comparing Novo Nordisk's prices charged to ... about how insurance conglomerates are taking in record profits or how PBMs are being investigated ...

Derek Saul has covered markets for the Forbes news team since 2021. Danish pharmaceutical giant Novo Nordisk reported the most robust quarterly profits and sales in its history Thursday ...

Eli Lilly's shares jumped to a record high following a better-than-expected earnings report, while ... More shares of Novo Nordisk skyrocketed on the heels of a promising clinical trial.

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 (see chart 2). Lilly’s edge rests on a more effective drug, better execution, ...

Wegovy sales continued to soar, recording DKK 17.4 billion in sales, representing a surge of 83%, driven by high prescription rates and Novo Nordisk’s efforts to meet the same. Year to date ...

The stock is up 8.55% over the last year and 7.45% year-to-date. Let’s look at what the charts indicate for Novo Nordisk stock and how the stock maps against Wall Street estimates. Novo Nordisk ...

(SOUNDBITE OF ARCHIVED RECORDING) BERNIE SANDERS: But you still have not answered my question - it's a very simple question - why Novo Nordisk is charging Americans substantially higher prices for ...